2-Hydroxybenzylamine (2-HOBA) to prevent early recurrence of atrial fibrillation after catheter ablation: protocol for a randomized controlled trial including detection of AF using a wearable device - O’Neill, Matthew J.; Yoneda, Zachary T.; Crawford, Diane M.; Ye, Fei; Ao, Mingfang; Pitchford, Lisa M.; Rathmacher, John A.; Murray, Katherine T.; Akers, Wendell S.; Roden, Dan M.; Michaud, Gregory F.; Shoemaker, M. Benjamin (Current controlled trials in cardiovascular medicine, 2021)
Keywords: 2-HOBA; Ablation; Alzheimer's disease; Atrial fibrillation; Atrial Fibrillation - diagnosis; Atrial Fibrillation - prevention & control; Atrial Fibrillation - surgery; Benzylamines; Biomedicine; Cardiac arrhythmia; Catheter Ablation - adverse effects; Catheters; Clinical trials; Diseases; Health aspects; Health Sciences; Heart; Humans; Inflammation; Informed consent; Isolevuglandin; Materia medica, Vegetable; Medicine; Medicine & Public Health; Natural products; Neoplasm Recurrence, Local; Organic compounds; Oxidative stress; Pharmaceutical Preparations; Pharmacokinetics; Plant extracts; Prevention; Pulmonary vein isolation; Randomized Controlled Trials as Topic; Reactive oxygen species; Relapse; Smartwatches; Statistics for Life Sciences; Study Protocol; Testing; Thoracic surgery; Wearable computers; Wearable Electronic Devices; United States; United States--US; Nashville Tennessee; Reactive oxygen species; Apple Watch; Chromosome 4q25; Atrial fibrillation; Isolevuglandin; Ablation; Pulmonary vein isolation; 2-HOBA; PITX2